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Uromodulin-associated kidney disease (UAKD) is a dominant heritable renal disease in humans which is caused
by mutations in the uromodulin (UMOD) gene and characterized by heterogeneous clinical appearance. To get
insights into possible causes of this heterogeneity of UAKD, we describe the new mutant mouse line UmodC93F,
leading to disruption of a putative disulfide bond which is also absent in a known human UMOD mutation, and
compare the phenotype of this new mouse line with the recently published mouse line UmodA227T. In both mutant
mouse lines, which were both bred on the C3H background, the Umod mutations cause a gain-of-toxic function
due to a maturation defect of the mutant uromodulin leading to a dysfunction of thick ascending limb of Henle’s
loop (TALH) cells of the kidney. Umod mutant mice exhibit increased plasma urea and Cystatin levels, impaired
urinary concentration ability, reduced fractional excretion of uric acid and nephropathological alterations in-
cluding uromodulin retention in TALH cells, interstitial fibrosis and inflammatory cell infiltrations, tubular atro-
phy and occasional glomerulo- und tubulocystic changes, a phenotype highly similar to UAKD in humans. The
maturation defect of mutant uromodulin leads to the accumulation of immature uromodulin in the endoplasmic
reticulum (ER) and to ER hyperplasia. Further, this study was able to demonstrate for the first time in vivo that the
severity of the uromodulin maturation defect as well as onset and speed of progression of renal dysfunction and
morphologicalalterationsare strongly dependent on theparticularUmodmutation itself and thezygosity status.
INTRODUCTION
Uromodulin-associated kidney disease (UAKD) is an
autosomal-dominant hereditary and slowly progressive disorder
caused by mutations of the uromodulin (UMOD) gene (1,2).
UAKD summarizes several clinically defined diseases including
medullary cystic kidney disease type 2 (MCKD2; OMIM
#603860), familial juvenile hyperuricemic nephropathy
(FJHN; OMIM #162000) and glomerulocystic kidney disease
(GCKD; OMIM #609886). To date, more than 70 distinct
UAKD-causing UMOD mutations are known (3–5). The clinic-
al manifestations of UAKD are hypouricosuric hyperuricemia,
gout, mild defects in urine concentrating ability and it has a vari-
able rate of disease progression between individuals leading to
renal failure (1,6,7). Tubulointerstitial fibrosis with moderate in-
flammatory cell infiltration, tubular atrophy and cysts were
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described as histological alterations of the kidneys of UAKD
patients (4,8). Hyperuricemia is mostly the first clinical sign
which is diagnosed in UAKD patients, however, it is manifested
in most but not all UAKD patients (7). Inconstant clinical signs,
diagnosed in some patients, are small kidneys probably due to
progressive renal scarring, hypertension and, in one report of
patients harboring an UMOD indel-mutation, upper urinary
tract infection (5,9,10). Further, time-point of first diagnosis of
UAKD and rate of decline of kidney function varies within
and between affected families and, comparing 37 distinct
UMOD mutations in UAKD patients belonging to 45 families,
no correlation of severity of clinical symptoms and the corre-
sponding causative UMOD mutation could be drawn (2,11).
Uromodulin was originally identified over 60 years ago as
Tamm-Horsfall glycoprotein and is the most abundant protein
in mammalian urine (12,13). It is synthesized exclusively and
abundantly in the cells of the thick ascending limb of Henle’s
loop (TALH) without macula densa cells and of the early part
of the distal convoluted tubule (14). Human mature uromodulin
glycoprotein consists of 590 amino acids with 48 cysteines and
eight potential N-linked glycosylation sites (13), of which
seven appear to be occupied (15). It is anchored at the luminal
membrane of TALH cells by a GPI-anchor and is released in
the urine by proteolytic cleavage (16). Haploinsufficiency of
uromodulin does not cause UAKD as demonstrated by Umod
knockout mice (17,18). All but four (in-frame deletions) UAKD-
causing UMOD mutations are missense changes predicted to
cause protein misfolding (3,4). Mutant uromodulin proteins
show delayed ER to Golgi trafficking (6,19). The recently char-
acterized mutant mouse line UmodA227T enabled the classifica-
tion of an uromodulin mutation as gain of toxic function
mutation causing TALH dysfunction and clinical signs (20).
In various genome-wide association (GWAS) studies,
common allelic UMOD variants were identified to be associated
with increased risk for complex traits such as chronic kidney
disease, altered plasma uric acid levels or kidney stones (21–
23). Thus, common allelic UMOD promoter variants influence
UMOD expression, leading to altered plasma uric acid levels
(24). As reviewed by Rampoldi et al. (4), the common allelic
UMOD variants detected in GWAS studies lead to increased
urinary uromodulin levels and the pathophysiology of this is so
far nearly unknown. In contrast, rare allelic UMOD variants
which affect amino acid sequence lead to UAKD associated
with uromodulin trafficking defect and decreased urinary uro-
modulin levels.
We recently described the UAKD phenotype of the mutant
mouse line UmodA227T (20). The aim of the present study was
to characterize a second chemically induced Umod mutant
mouse line called UmodC93F and to analyze the effects of differ-
ent Umod mutations (UmodA227T and UmodC93F) and of allelic
status of Umod mutant mice on onset, severity and progression
of clinical phenotype and morphological kidney alterations.
RESULTS
Establishment of the mutant mouse line UmodC93F
The generation of the chemically induced mutant mouse line
UREHD1 within the Munich ENU mouse mutagenesis project
was described previously (25). This mouse line exhibited
increased plasma urea levels, which was heritable in an
autosomal-dominant manner. Linkage analyses revealed
linkage of the causative mutation to a defined single chromosom-
al site on chromosome 7 between 116.8 (D7Mit40) and
125.3 Mb (D7Mit68). The strongest linkage of the causative mu-
tation was observed with the polymorphic marker D7Mit238
(119.1 Mb). The probability of the existence of confounding
non-segregating mutations in the detected chromosomal
region is P , 0.001 (26). Sequence analysis of Umod cDNA,
whose gene is located at 119.5 Mb on chromosome 7, revealed
a GT transversion in exon 3 at nt 470 (NM_009470) (Supple-
mentary Material, Fig. S1A). Genotypic differentiation was
enabled by allele-specific PCR reactions (Supplementary Mater-
ial, Fig. S1B). Mating of heterozygotes to wild-type mice and of
heterozygous mutant mice showed the expected Mendelian
pattern of inheritance of the mutation in the offspring.
The identified mutation leads to an amino acid substitution of
cysteine to phenylalanine at position 93 of uromodulin. Thus, the
nephropathic line was named Munich UmodC93F mutant mouse
line. C93 is assumed to form a disulfide bond with C105 (Supple-
mentary Material, Fig. S1C). Hence, the disulfide bond C93–
C105 is absent in mutant uromodulin, as it is also the case in
the human uromodulin protein derived from the mutant allele
UMODC106Y.
Clinical and clinical-chemical data of adult UmodC93F
mutant mice
Detailed clinical and clinical-chemical analyses were carried out
on UmodC93F mutant mouse line. In 8-month-old heterozygous
UmodC93F mutants, plasma urea levels were increased 2-fold
in both genders compared with their wild-type littermate con-
trols (Table 1). Mutants also exhibited significantly increased
plasma creatinine levels. A moderate but significant increase
of potassium, calcium and alkaline phosphatase was detected
in mutants of both genders. In contrast, mutants of both
genders exhibited a significant decrease of triglycerides, ferritin
and transferrin. Cholesterol was significantly decreased in male
heterozygotes, and iron as well as inorganic phosphorus was sig-
nificantly decreased in female heterozygotes. Plasma magne-
sium levels determined in 9-month-old mice were not
significantly different between male (0.64+ 0.06 mmol/l) and
female (0.72+ 0.12 mmol/l) heterozygous UmodC93F mutants
versus wild-type littermates (male: 0.68+ 0.07 mmol/l;
female: 0.73+ 0.05 mmol/l).
In 9-month-old heterozygous UmodC93F mutant mice, a 1.7-
to 2.1-fold increase in daily urine volume and a significant
decrease in urine osmolality were detected compared with wild-
type controls (Table 2; Supplementary Material, Fig. S2A and
B). Daily urinary excretion of several solutes was significantly
different in mutants compared with wild-type controls. Thus,
urine-to-plasma concentration ratios (U/P) for sodium, potas-
sium and chloride were significantly reduced, whereas 24 h
excretion and fractional excretion (FE) of these solutes were
increased. All parameters were altered significantly except for
24 h excretion of sodium (P ¼ 0.11) and chloride (P ¼ 0.06)
in heterozygous mutant males. A 3-fold increased 24 h urinary
excretion of calcium was associated with significantly increased
U/P and FE of calcium. Also the FE and 24 h excretion of mag-
nesium, a further divalent cation which is transported mainly
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paracellularly at the TALH segment like calcium, were signifi-
cantly increased in heterozygous mutants of both genders com-
pared with wild-type controls. Further, although daily urea
excretion was increased in mutants (males: P ¼ 0.05, females:
P , 0.05), U/P and FE of urea were decreased. In contrast to
all solutes mentioned above whose daily urinary excretion
were increased, 24 h excretion of uric acid was distinctly
decreased. Also U/P and FE of uric acid were significantly
decreased in heterozygotes. Despite deprivation of drinking
water, heterozygotes still excreted more urine than wild-type
controls (males: P ¼ 0.07, females: P ¼ 0.09), whereas urine
osmolality remained significantly decreased (Table 2).
Urinary excretion of uromodulin was markedly decreased in
UmodC93F mutant mice of both genders (Supplementary Mater-
ial, Fig. S2C). Uromodulin excretion in homozygous mutant
mice was more distinctly decreased than in heterozygotes, but
they still excreted small amounts of mutant uromodulin. The
size of the uromodulin proteins detected in urine of homozygous
Table 1. Plasma data of 8-month-old heterozygous UmodC93F mutant mice
Male Female
Wild-type Heterozygous Wild-type Heterozygous
Na+ (mmol/l) 150.7+3.5 152.4+1.6 147.8+2.4 149.4+1.3
K+ (mmol/l) 4.71+0.40 5.16+0.26∗∗ 4.02+0.24 4.68+0.07∗∗∗
Ca2+ (mmol/l) 2.21+0.06 2.27+0.04∗ 2.17+0.05 2.27+0.05∗∗∗
Cl2 (mmol/l) 116.7+2.7 116.4+1.8 113.7+2.5 112.9+1.9
Pi (mmol/l) 1.56+0.19 1.23+0.49 1.30+0.33 0.88+0.19∗∗
Total protein (g/l) 54.4+1.3 54.0+0.9 52.8+1.9 52.0+2.3
Albumin (g/l) 28.7+1.0 28.8+1.0 29.4+1.6 29.8+0.6
Creatinine (mmol/l) 9.1+1.3 10.3+0.9∗ 10.5+1.4 12.4+1.2∗∗
Urea (mmol/l) 9.6+1.0 21.2+2.1∗∗∗ 10.2+2.3 19.2+2.3∗∗∗
Cholesterol (mmol/l) 4.88+0.30 4.20+0.28∗∗∗ 3.43+0.34 3.18+0.21
Triglycerides (mmol/l) 4.55+0.99 3.52+0.76∗ 4.52+0.89 3.22+0.61∗∗
LDH (U/l) 142.8+52.5 123.3+30.7 143.9+25.4 145.5+34.5
ALAT (U/l) 34.2+12.8 27.6+8.8 26.4+2.5 24.6+6.3
ASAT (U/l) 48.0+24.9 42.2+7.0 42.4+3.7 47.0+9.4
AP (U/l) 80.7+5.7 106.0+10.8∗∗∗ 135.0+20.2 169.0+17.5∗∗∗
Glucose (mmol/l) 8.27+0.70 7.61+0.92 8.24+0.61 7.92+1.51
Lactate (mmol/l) 10.5+1.2 10.0+2.1 9.5+1.1 9.7+1.8
Ferritin (mg/l) 33.6+18.2 20.0+6.2∗ 40.1+6.5 30.5+8.2∗∗
Transferrin (g/l) 1.59+0.04 1.49+0.05∗∗∗ 1.57+0.05 1.49+0.04∗∗
Iron (mmol/l) 31.5+4.1 28.0+4.2 33.7+3.8 28.7+3.2∗∗
Data are means+SD. n ¼ 9–10 per genotype and gender.
Pi, inorganic phosphorus; LDH, lactate dehydrogenase (EC 1.1.1.27); ALAT, alanine aminotransferase (EC 2.6.1.2); ASAT, aspartate aminotransferase (EC 2.6.1.1);
AP, alkaline phosphatase (EC 3.1.3.1).
UmodC93F heterozygous mutant versus wild-type: ∗P , 0.05; ∗∗P , 0.01; ∗∗∗P , 0.001.
Table 2. Urine data of adult mice under basal conditions and after deprivation of drinking water for 18 h
Male Female
Wild-type Heterozygous Wild-type Heterozygous
Body weight (g) 37.3+4.1 26.6+1.3∗∗∗ 36.3+3.1 23.7+0.9∗∗∗
Drinking water ad libitum
Water intake (ml/day) 5.08+2.63 5.96+1.30 4.01+1.22 5.85+0.95∗∗
Urine volume (ml/day) 1.33+1.02 2.23+0.84P ¼ 0.058 0.96+0.32 2.04+0.54∗∗∗
Urine osmolality (mOsm/kg H2O) 2517+774 1687+457∗ 2964+661 1727+208∗∗∗
Na+ (mmol/day) 176+46 226+76 170+30 238+63∗
K+ (mmol/day) 430+101 620+178∗ 424+92 598+145∗
Ca2+ (mmol/day) 2.8+2.3 9.0+4.0∗∗ 2.6+0.6 8.1+3.6∗∗
Cl2 (mmol/day) 217+55 282+79P ¼ 0.061 204+44 284+74∗
Mg2+ (mmol/day) 29.1+9.8 44.0+12.9∗ 32.5+8.8 51.3+13.7∗∗
Creatinine (mmol/day) 5.8+1.4 6.7+1.9 5.8+0.8 5.4+1.0
Urea (mmol/day) 1.5+0.4 2.0+0.5P ¼ 0.052 1.5+0.3 1.9+0.3∗
Uric acid (nmol/day) 932+276 283+91∗∗∗ 1368+160 475+91∗∗∗
Glucose (mmol/day) 2.1+0.7 2.0+0.7 2.5+0.4 2.0+0.3∗∗
Total protein (mg/day) 10.5+3.0 6.6+2.5∗∗ 2.1+0.7 0.8+0.2∗∗∗
Deprivation of drinking water for 18 h
Urine volume (ml) 0.64+0.36 0.97+0.34P ¼ 0.068 0.49+0.26 0.73+0.30 P ¼ 0.087
Urine osmolality (mOsm/kg H2O) 3743+631 2498+377∗∗∗ 3898+799 2568+443∗∗
Age of mice analyzed: 9 month. Data are means+SD. n ¼ 6–10 per genotype and gender (details see Supplementary Material, Table S1).
UmodC93F heterozygous mutant versus wild-type: ∗P , 0.05; ∗∗P , 0.01; ∗∗∗P , 0.001.
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and heterozygous UmodC93F mutant mice corresponded to that
of the wild-type uromodulin band.
The analysis of the skeleton, performed by DXA analysis,
showed that bone-mineral density and bone-mineral content
were significantly decreased in 9-month-old heterozygous
mutants of both genders, indicating osteopenia (Table 3).
In conclusion, the mouse line UmodC93F exhibited similar
clinical characteristics as the mouse line UmodA227T and
UAKD-affected patients.
Characterization of the uromodulin trafficking defect
On light microscopy, kidneys of 4-month-old UmodC93F
mutants exhibited only discrete histological alterations
(Fig. 1), including intracytoplasmic inclusions in TALH cells,
visible in Masson-Trichrome-stained paraffin sections
(Fig. 1A) and in toluidine blue-stained semi-thin sections
(Fig. 1B). Immunohistochemical analysis for uromodulin
demonstrated distinct apical membrane staining and weak
diffuse homogeneous cytoplasmic staining for uromodulin in
TALH cells of wild-type control mice (Fig. 1C left). In contrast,
cells of the TALH of mutants exhibited more intense uromodulin
staining, which was located intracytoplasmically in the peri-
nuclear compartment (Fig. 1C right), already present at 2
weeks of age (Fig. 1D). Ultrastructural evaluations of TALH
cells demonstrated intracytoplasmic perinuclear stacked lamel-
lar structures (Fig. 1E).
To explore if these lamellar structures represent hyperplastic
bundles of the ER, double-immunofluorescence analyses of uro-
modulin with markers for ER (PDI, BiP) and Golgi apparatus
(giantin) were performed (Fig. 1F). Strong co-localization of
mutant uromodulin with PDI and BiP in TALH cells of
UmodC93F mutant mice was detected, whereas there was no
co-localization with giantin. Similar co-localization of mutant
uromodulin to the ER marker but not to the Golgi apparatus
marker was also observed in TALH cells of UmodA227T
mutant mice (data not shown). Due to the structural alterations
of TALH cells in Umod mutant mice, we performed immunohis-
tochemical analyses for NKCC2, an ion transporter located at the
apical membrane of TALH cells, to evaluate if the polarity of
TALH cells is affected in mutant mice (Fig. 1G). NKCC2 was
localized at the apical membrane of TALH cells in wild-type
mice as well as in Umod mutant mice of both lines indicating
maintenance of TALH cell polarity.
Further, we carried out western blot analyses of kidney
extracts from both Umod mutant mouse lines (Fig. 1H). Renal
uromodulin protein abundance in wild-type mice was detected
at a very low level and its molecular weight corresponded to
the fully glycosylated mature uromodulin protein excreted
with urine. In contrast, abundance of uromodulin protein in
kidneys of Umod mutant mice was remarkably higher when
compared with wild-type mice, and it consisted predominantly
of the immature uromodulin protein. Further, uromodulin
protein abundance was higher in homozygous UmodA227T
mutant mice when compared with UmodA227T heterozygotes.
Signal intensities between UmodA227T homozygotes and
UmodC93F heterozygotes were similar. Moreover, the main
fraction of uromodulin detected in kidneys of mutant mice con-
sisted of lower molecular weight immature protein (100 kDa)
than the fully glycosylated uromodulin protein excreted with
urine.
Onset of the increase of plasma urea in mutant lines
UmodC93F and UmodA227T
In line UmodC93F, 2-week-old heterozygotes exhibited urea
levels similar to those of age-matched wild-type littermates
(Fig. 2A, Supplementary Material, Fig. S3). At 4 weeks of age,
the median of plasma urea concentration tended to be increased
in heterozygotes males. At 7 weeks of age, the median of plasma
urea levels was significantly increased in female heterozygous
mutants and tended to be increased in male heterozygotes.
Three-month-old heterozygous UmodC93F mutant mice of both
genders exhibited significantly increased plasma urea levels
compared with wild-type littermate controls. In contrast to het-
erozygotes, blood urea levels were already significantly
increased in male and female homozygotes from 2 weeks of
age onwards.
In line UmodA227T, 2-week-old homozygotes and heterozy-
gotes exhibited urea levels similar to those of age-matched wild-
type littermates (Fig. 2B) (20). At 7 weeks of age, plasma urea
levels were moderately but significantly increased in homozy-
gous UmodA227T mutants of both genders, resembling the
mean urea level of 7-week-old heterozygous UmodC93F mutant
mice. Four-month-old homozygous and heterozygous
UmodA227T mutant mice of both genders exhibited significantly
increased plasma urea levels compared with wild-type littermate
controls.
Table 3. DXA analysis of weight- and bone-related parameters of adult mice
Male Female
Wild-type Heterozygous Wild-type Heterozygous
Body weight (g) 38.0+2.0 29.1+1.0∗∗∗ 36.3+6.1 25.2+1.5∗∗∗
Fat mass (units) 13.7+3.2 4.3+1.2∗∗∗ 16.1+6.8 3.0+1.3∗∗∗
Fat content (units × 100/g) 35.9+6.6 14.7+3.9∗∗∗ 43.6+15.4 11.8+5.1∗∗∗
BMD (mg/cm2) 62.9+1.9 53.3+2.1∗∗∗ 65.7+4.0 53.7+2.8∗∗∗
BMC (mg) 853+150 540+35∗∗∗ 887+213 491+47∗∗∗
Bone content (%) 2.24+0.31 1.85+0.09∗∗ 2.45+0.48 1.94+0.12∗∗
Age of mice analyzed: 9 month. Data are means+SD. n ¼ 10 per genotype and gender.
BMD, bone mineral density; BMC, bone mineral content.
UmodC93F heterozygous mutant versus wild-type: ∗P , 0.05; ∗∗P , 0.01; ∗∗∗P , 0.001.
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Comparison of the severity of the decrease of uromodulin
excretion between both Umod mutant mouse lines
Urinary excretion of uromodulin was markedly decreased in het-
erozygous UmodC93F mutant mice compared with wild-type lit-
termate controls (Fig. 2C). The extent of the decrease in
uromodulin excretion in UmodC93F heterozygotes was similar
to that of UmodA227T homozygotes. In both Umod mutant
mouse lines, uromodulin excretion in homozygous mutant
mice was more distinctly decreased than in heterozygotes (Sup-
plementary Material, Fig. S2C) (20).
Impact of the Umod mutation on body weight, body
composition and postnatal body growth
Nine-month-old heterozygous UmodC93F mutants of both
genders exhibited a 23–30% lower body weight and a 69–
81% reduced fat mass compared with wild-type controls
(Table 3). In the mutant mouse line UmodA227T, adult mutant
mice also exhibited a lower body weight compared with age-
matched littermate controls (20). To evaluate the onset of the dif-
ferences in body weight, we monitored the body weight gain by
weighing the animals of the mouse line UmodC93F from the day
of birth up to 16 weeks of age (Fig. 3). Birth weight did not differ
between genotypes. Four-week-old heterozygous mutant males
exhibited a significantly reduced body weight compared with
wild-type controls, whereas body weight of heterozygotes and
wild-types became significantly different from 7 weeks of age
onwards in females. Body weights of homozygous mutants of
both genders were significantly lower than those of wild-type lit-
termates from 5 weeks of age onwards.
Clinical-chemical and morphological kidney findings in
aged Umod mutant mice with respect to type of mutation
and zygosity
With age, there was a continuous increase of blood urea concen-
trations in Umod mutant mice of both lines (Fig. 4A). Urea excre-
tion and in consequence blood urea concentrations are strongly
influenced by the proper tubular function in building up and
maintaining of renal corticomedullary urea concentration gradi-
ent, similar to the role of salt ions for the corticomedullary
osmotic gradient (27). Homozygous mutants had constantly
higher blood urea levels than age-matched heterozygous
mutant littermates. Further, the increase in blood urea concentra-
tion in the UmodC93F mouse line was stronger than in age-
matched UmodA227T mutants of the same allelic status.
Further, plasma Cystatin C concentrations, which represent a
robust endogenous marker of glomerular filtration rate (28),
were significantly increased in homozygous mutants of both
lines compared with wild-type littermates at an age of 4
months (Fig. 4B). The Cystatin concentrations did not signifi-
cantly differ between homozygous UmodA227T mutants and
homozygous UmodC93F mutants. At an age of 20–22 months,
Umod mutants of both lines had significantly increased Cystatin
levels compared with wild-type mice, and homozygous
UmodC93F mutants exhibited distinctly increased plasma Cysta-
tin C concentrations compared with homozygous UmodA227T
mutants.
Morphological kidney alterations in aged Umod mutant mice
comprised interstitial fibrosis and tubular atrophy (IFTA) as well
as interstitial infiltrates of inflammatory mononuclear cells,
which were mainly localized in the corticomedullary region
(Fig. 5A and B). Further, dilatations and cysts of various
tubular segments and of Bowman’s capsule were inconstant
findings in kidneys of aged mutant mice (Fig. 5C). Aged
mutants, preferentially of the mouse line UmodC93F, exhibited
a dilation of the renal pelvis. Immunohistochemical detection
of uromodulin in kidneys of aged Umod mutant mice revealed,
in contrast to young mice, a heterogeneous staining pattern in
TALH profiles (Fig. 5D and E). There were TALH profiles
where some cells exhibited a strong perinuclear uromodulin
immunostaining pattern as seen in TALH cells of young-adult
Umod mutant mice, whereas other cells of the same TALH
profile showed discrete or nearly no uromodulin staining.
Ultrastructural analysis of TALH cells of aged Umod mutants
revealed distinct intracytoplasmic perinuclear stacked lamellar
structures as seen in young-adult Umod mutant mice, occasion-
ally filling most of the cytoplasmic compartment (Fig. 5F).
However, there were also TALH cells with strongly dilated
hyperplastic ER in the perinuclear intracytoplasmic compart-
ment, whereas other cells exhibited only discreet or no hyper-
plastic ER. Hyperplastic ER bundles appeared heterogeneous
(Fig. 5G). Thus, in the majority of the TALH cells, hyperplastic
ER presented as perinuclear parallel-folded smooth lamellar
membranous structures. Other TALH cells contained
dilated hyperplastic ER with moderate electron dense material
included.
To evaluate putative effects of type of mutation and zygosity
on severity of advanced kidney alterations, the two predominant
and consistently found kidney alterations IFTA and inflamma-
tory cell infiltrates were quantified with unbiased stereological
methods in kidneys of 20- to 22-month-old male mice of the
lines UmodA227T and UmodC93F (Fig. 6). Volume fractions as
well as total volumes of IFTA (Vv(IFTA/kid) and V(IFTA,kid), re-
spectively) were significantly higher in homozygous mutants
than in heterozygous mutant littermates and were distinctly
higher in UmodC93F mutants than in UmodA227T mutants with
the same zygosity. Vv(IFTA/kid) and V(IFTA,kid) of heterozygous
UmodA227T mutants were similar to wild-type levels. Volume
fractions as well as total volumes of inflammatory cell infiltrates
(Vv(IC/kid) and V(IC,kid), respectively) were significantly
increased in 20- to 22-month-old UmodC93F homozygotes and
heterozygotes and in UmodA227T homozygotes compared with
age-matched wild-type mice, but were nearly indifferent when
compared between these mutant groups. Vv(IC/kid) and V(IC,kid)
of heterozygous UmodA227T mutants were similar to wild-type
levels.
DISCUSSION
Various clinical phenotypes occur in humans harboring a muta-
tion within the UMOD gene and suffering from UAKD. Further,
important differences in severity, onset and rate of progression of
kidney disease and in age at onset of end-stage renal disease
(ESRD) were observed in UAKD affected patients (5). Time-
point of first diagnosis of UAKD and rate of decline of kidney
function varies also within affected families harboring the
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Figure 1. Characterization of the uromodulin trafficking defect. (A and B) TALH cells of a 4-month-old heterozygous UmodC93F mutant mouse contain focal intra-
cytoplasmic inclusions of lamellated trichrome blue material, visible in the Masson-Trichrome (A) and toluidine blue (B) stained kidney section and highlighted by
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same mutation. In a study including 37 different UAKD-causing
UMOD mutations, no relationship between onset and severity of
clinical signs as well as renal disease progression and the causa-
tive mutation could be demonstrated in humans (5). Important
environmental factors or modifier genes were assumed to modu-
late the clinical UAKD phenotype (5). The two mouse lines
UmodC93F and UmodA227T harbor a mutation within the Umod
gene and exhibit a progressive renal phenotype with an impair-
ment in the urinary concentrating ability, strongly reduced frac-
tional excretion of uric acid, altered divalent mineral cation
metabolism and progressive morphological kidney alterations,
which are features highly similar to the characteristics of
human UAKD. Both Umod mutant mouse lines, which are
housed under the same environmental conditions, originate
from the same C3H inbred strain and differ only in the Umod mu-
tation, therefore making them unique animal models for deter-
mining the mutation-specific impact on onset, severity and
progression of renal dysfunction in UAKD.
The point mutation of the line UmodC93F leads to the amino
acid exchange C93F resulting in the loss of the putative disulfide
bond C93–C105 (www.uniprot.org/uniprot/Q91X17). In
UAKD-affected humans, many known UMOD mutations
affect the amino acid cysteine. From the more than 70 known
UMOD mutations at more than 50 amino acid positions, 23 dif-
ferent cysteines are affected, thereof one is C106Y correspond-
ing to murine C105 (3–5). Formation of intrachain disulfide
bonds might be essential to exhibit the accurate tertiary structure
of uromodulin. Thus, many UMOD mutations resulting in a
UAKD disease phenotype cause disruption of the molecule’s
stable tertiary structure, resulting in altered protein folding, re-
tention within the endoplasmic reticulum (ER) and impaired
trafficking (6). Similar to the immunohistochemical renal data
of affected humans and of UmodA227T mutant mice (2,6,8,20),
massive intracellular accumulation of immature uromodulin
was detected in TALH cells of UmodC93F mutant mice. Thus,
the immature, not fully glycosylated uromodulin was retained
in the ER of TALH cells of mutant mice. Further, intratubular
heterogeneity of uromodulin immunostaining in TALH cells,
found in aged Umod mutant mice, was described also in
UAKD-affected humans (29). In consequence, the ER became
hyperplastic and the protein abundance of molecular chaperones
like PDI or BiP (29) was strongly increased in TALH cells, indi-
cating the initiation of unfolded protein response (UPR) (30,31).
In consequence, protein misfolding of mutant uromodulin might
compromise ER homeostasis and volume expansion of the ER.
Thus, the activation of transcription of molecular chaperones
like BiP has been described as a cellular mechanism to increase
protein-folding capacity and to reduce ER stress (30,32). Further
studies are necessary to get more insights into the mechanisms of
UAKD associated ER stress. The Golgi apparatus of TALH cells
appeared to be unaffected, as no co-localization of uromodulin
with giantin was detected. Maturation retardation of mutant uro-
modulin also impeded protein folding and processing of native
uromodulin protein to the apical membrane of TALH cells and
its release and excretion in the urine. Thus, uromodulin excretion
in heterozygous UmodC93F mutant mice was decreased to ,50%
of wild-type levels caused by the dominant negative effect of
mutant protein on the maturation of native uromodulin. In
UAKD patients, a strong decrease of uromodulin excretion
was a nearly constant finding in heterozygous UMOD mutation
carriers (6,9,33,34). In consequence of the severe structural
alterations of TALH cells due to ER hyperplasia and disturbance
of ER homeostasis, TALH dysfunction occurs. The mechanism
of TALH dysfunction was already proposed in the description of
the mutant mouse line UmodA227T (20) and is now supported by
the results of kidney function analyses of UmodC93F mutant
mice. However, at least the polarity of TALH cells seemed to
be intact in both Umod mutant mouse strains, as the ion transport-
er NKCC2 remained strictly located at the apical membrane of
TALH cells. UAKD in humans is described as progressive
renal disease which inconstantly can lead to end-stage kidney
disease (8,35). Advanced histological alterations, which can be
observed in kidneys of humans suffering from UAKD, are tubu-
lointerstitial fibrosis, interstitial infiltrates of inflammatory
mononuclear cells, tubular atrophy and, in approximately
one-third of patients, uni- or bilateral tubular or glomerular
cysts (5,6,8,36–40), alterations which we also observed in
kidneys of aged Umod mutant mice of both mouse lines. Long-
lasting ER stress of TALH cells might induce a profibrotic and
proinflammatory microenvironment leading to peritubular fibro-
sis and mononuclear infiltrates, beginning in the corticomedul-
lary TALH region. Of note, impaired ER function of renal
tubular cells might increase vulnerability to ER stress and, if
ER dysfunction is long-lasting, it leads to peritubular fibrosis
and tubular atrophy (41). Tubulo-interstitial fibrosis represents
the hallmark of progression of chronic kidney disease, and epi-
thelial damage can initiate a pro-fibrotic microenvironment
(42). Increase of the severity of the uromodulin maturation
stars. (C) Representative TALH profile immunohistochemically stained for uromodulin of a 4-month-old wild-type (left) and heterozygous UmodC93F mutant (right)
mouse. In wild-type mice, weak diffuse homogeneous cytoplasmic and distinct apical membrane staining for uromodulin in TALH cells was observed. TALH cells of
mutants exhibited a strong perinuclear staining intensity in the cytoplasm. (D) Representative TALH profile immunohistochemically stained for uromodulin of
2-week-old wild-type (left), heterozygous (middle) and homozygous (right) UmodC93F mutant mice. Intracytoplasmic accumulation of uromodulin was already
present in mutants at an age of 2 weeks. (E) Representative electron micrograph of TALH cells of a 4-month-old heterozygous UmodC93F mutant mouse; final mag-
nification×4000,final magnification of insert×20 000. TALH cells contained intracytoplasmic inclusionscomposedof perinuclear stacked lamellar structures (mag-
nification in insert). (F) ER retention of uromodulin in TALH cells of a heterozygous UmodC93F mutant mouse, demonstrated by confocal laser scanning microscopy.
Uromodulin is co-localized with the molecular chaperones PDI (upper row) and BiP (middle row), localized in the ER, but not with giantin (lower row), which is
localized in the Golgi apparatus. Of further interest is the strong expression of PDI and BiP in TALH cells, indicating hyperplasia of ER. (G) Representative
TALH profiles immunohistochemically stained for NKCC2 of a 4-month-old wild-type, a 4-month-old heterozygous UmodC93F mutant and a 3-month-old homozy-
gous UmodA227T mutant mouse. The ion transporter NKCC2 is localized at the apical membrane of TALH cells in wild-type mice as well as in Umod mutant mice of
both lines demonstrating that accurate polarity of TALH cells is present in Umod mutant mice. (H) Analysis of uromodulin protein abundance in whole kidney homo-
genates of 3-month-old wild-type and Umod mutant mice. In kidneys of wild-type mice, uromodulin is abundant at a very low level, and its molecular size corre-
sponded to the fully glycosylated uromodulin protein excreted with urine. In contrast, molecular weight of the main fraction of uromodulin detected in mutant
mice was lower than the fully glycosylated uromodulin protein excreted with urine, indicating the accumulation of immature uromodulin in kidneys of Umod
mutant mice. Uromodulin abundance in kidneys of Umod mutant mice was remarkably higher when compared with wild-type mice. M, protein molecular weight
marker; wt, wild-type mouse, het, heterozygous mutant mouse, homo, homozygous mutant mouse; U, urine.
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Figure 2. Onset and severity of the clinical phenotype of UmodC93F and UmodA227T mutant mice. (A) Analysis of the onset of the increase of plasma urea of UmodC93F
mutant mice. Data points show means+SEM. n ¼ 5–22 per genotype and gender (details see Supplementary Material, Table S1). (B) Analysis of the onset of the
increase of plasma urea of UmodA227T mutant mice. Data points show means+SEM. n ¼ 4–18 per genotype and gender (details see Supplementary Material,
Table S1). (A and B) Umod mutants versus wild-type: ∗P , 0.05; ∗∗P , 0.01; ∗∗∗P , 0.001. (C) Urine analysis of uromodulin excretion demonstrates that uromo-
dulin excretion of UmodC93F heterozygotes and UmodA227T homozygous mutants is decreased at a similar range compared with wild-type controls. (A–C) Wt, wild-
type; het, heterozygous mutant; homo, homozygous mutant. The corresponding mutant mouse line is indicated.
Figure 3. Postnatal body growth of UmodC93F mutant mice. Growth curves of UmodC93F mutant mice shows that significantly decreased body weights of mutant mice
were present already at an age of 4 weeks in males and of 5 weeks in females. Data points show means. Age 0–10 weeks: n ¼ 11–48 per genotype and gender; age 11–
16 weeks: n ¼ 5–29 per genotype and gender (details see Supplementary Material, Table S1). ∗P , 0.05; ∗∗P , 0.01; ∗∗∗P , 0.001; ahomozygous versus wild-type;
bheterozygous versus wild-type; chomozygous versus heterozygous. Wt, wild-type; het, heterozygous mutant; homo, homozygous mutant.
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retardation and in consequence the ER stress of TALH cells
might result in higher occurrence of peritubular interstitial fibro-
sis. Renal dysfunction progresses with age in Umod mutant mice,
and progressed structural alterations like IFTA might contribute
to disease progression. Bohle et al. (43) postulated already more
than two decades ago that there might be a close correlation
between the degree of interstitial fibrosis and the loss of renal
urine concentrating ability in chronic kidney disease, regardless
of the primary pathological event (42).
The presumed sequence of events in the pathophysiology and
progression of UAKD is schematically summarized in Figure 7.
Thus, the initial event is a mutation of the uromodulin gene
leading to the disruption of the molecule’s physiological tertiary
structure. In consequence, the maturation of the mutant protein is
retarded; also affecting the processing of the native uromodulin
protein and leading to ER hyperplasia and UPR as well as to
decreased uromodulin excretion. To a certain degree, the uromo-
dulin trafficking defect might be compensated by TALH cells
until TALH dysfunction appears. TALH dysfunction can be
compensated to a certain degree from the other segments of
the nephron until clinical signs occur. Thus, 2-week-old
UmodC93F heterozygotes already exhibit retention of uromodu-
lin in TALH cells but no increase in plasma urea. This develop-
ment might occur as a cumulative process. After transgression of
Figure 4. Progression of the clinical phenotype of UmodC93F and UmodA227T mutant mice with age. (A) Progression of the clinical phenotype was demonstrated by
continuous increase of plasma urea of UmodA227T and UmodC93F mutant mice with age. Data points show means+SEM. n ¼ 3–22 per genotype and age group
(details see Supplementary Material, Table S1). (B) Plasma Cystatin C concentration in male homozygous UmodA227T and UmodC93F mutant and wild-type mice
at an age of 4 months and 20–22 months. Data show scatter dot plot and means. n ¼ 6 per genotype and age group. ∗P , 0.05; ∗∗P , 0.01; ∗∗∗P , 0.001; ahomo-
zygous versus wild-type; bheterozygous versus wild-type; chomozygous versus heterozygous of the same Umod mutant line; dhomozygous UmodC93F mutant versus
homozygous UmodA227T mutant. Wt, wild-type; het, heterozygous mutant; homo, homozygous mutant.
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an unknown threshold, kidney dysfunction becomes clinically
apparent. The cut-off level of the development of clinical signs
is highly dependent on the severity of the maturation defect of
uromodulin caused by the UMOD mutation. Thus, the amino
acid-exchange C93F caused a more severe uromodulin matur-
ation defect than A227T in mice, resulting in an earlier onset
and increased severity of clinical findings in mutant mice. Hall-
marks of early clinical appearance are reduced fractional excre-
tion of uric acid [leading to commonly observed hyperuricemia
in humans due to absent uricase activity which is preserved in
mice (44)], azotemia, mild defect in urinary concentration
ability and decreased uromodulin excretion. Long-term effect
of ER stress on TALH cells leads to chronic morphological
kidney alterations like interstitial fibrosis, tubular atrophy and
interstitial infiltrates of inflammatory cells. Occasionally,
tubular and glomerular cyst formation occurs, whose patho-
physiology is yet unknown.
Clinical phenotype, onset, severity and progression of UAKD
in humans are very heterogeneous, and no association between
the type of UMOD mutation and clinical appearance could be
proved so far. There were several attempts to classify UMOD
mutations (5,9,11). Thus, e.g. according to their results of in
vitro assays, Williams et al. (11) suggested to classify UMOD
mutations according to the severity of the protein maturation
defect: group A mutations showing reduced in vitro maturation
of uromodulin of about 50% when compared with wild-type, and
group B mutations showing maturation of about 25% of precur-
sor uromodulin. However, these authors found no correlation of
genotype and phenotype in vivo as no phenotypic differences of
clinical features in patients with group A mutations compared
with those with group B mutations were identified. Besides
the problems to confer in vitro results to the in vivo situation, add-
itional variables are discussed like genetic heterogeneity
(e.g. modifier genes) and/or different environmental conditions
Figure 5. Morphological kidney alterations of aged Umod mutant mice. (A and B) Consistently found morphological alterations in kidneys of Umod mutants were (A)
interstitial fibrosis and tubular atrophy (IFTA) and (B) interstitial infiltrates of inflammatory mononuclear cells, consisting predominantly of lymphocytes, located
predominantly in the corticomedullary region. (C) Cystic changes of Bowman’s capsule (left site) and tubules (right site). A: PAS-silver; B: Masson-Trichrom;
C: H&E. A–C: 20-month-old heterozygous UmodC93F mutant mice. (D and E) Representative kidney TALH profiles immunohistochemically stained for uromodulin
of a 20-month-old wild-type (D), as well as of a 20-month-old heterozygous UmodC93F mutant mouse (E). In the 20-month-old wild-type mouse, TALH segments are
arranged radially within the kidney, and staining of uromodulin in TALH cells were enforced in the apical membrane and weak, diffuse and homogenous in the cyto-
plasm (D). In contrast, TALH segments in the Umod mutant mouse kidneys appear disarranged (E, left side). Heterogeneity of uromodulin staining pattern is present
even within TALH profiles. TALH cells with distinct perinuclear uromodulin staining (asterisk) are present, whereas other TALH cells exhibit weak diffuse cytoplas-
mic staining pattern (arrow) or (nearly) no uromodulin staining (arrow head). Twenty-month-old heterozygous UmodC93F mutant mouse (E). (F and G) Ultrastructural
aspects of TALH cells of aged Umod mutant mice: some TALH cells exhibiting cytoplasm fully filled with stacked lamellar structures representing hyperplastic ER
(F). Heterogeneity of hyperplastic ER varied from perinuclear parallel-folded smooth lamellar membranous structures (G, left) to dilated hyperplastic ER including
diffuse moderate electron dense material (G, right). Twenty-one-month-old heterozygous UmodC93F mutant mice, final magnifications are indicated (F and G).
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(e.g. nutrition) potentially influencing onset, severity and pro-
gression of this kidney disease in humans (5) (Fig. 7, Table 4).
These parameters were highly standardized in the analyses of
our both Umod mutant mouse lines, as they differ genetically
only in their type of Umod mutation and were housed under iden-
tical environmental and nutritional conditions. The phenotype of
the lines UmodC93F and UmodA227T is highly similar, but they
differ in onset, severity and speed of progression of renal altera-
tions (Table 4). Maturation retardation of mutant C93F uromo-
dulin is much more severe than of mutant A227T uromodulin
protein. In consequence, TALH dysfunction becomes clinically
apparent at an earlier age and is more severe in UmodC93F
mutants than in UmodA227T mutant mice. In vitro analyses
demonstrated that also UMOD mutations identified in humans
differ in their potential to delay uromodulin maturation and traf-
ficking (9,11). The trafficking defect caused by mutant uromodu-
lin might also affect the trafficking of wild-type uromodulin
protein in heterozygotes as the uromodulin excretion of
UmodC93F heterozygous mutant mice is reduced to ,50% of
that of wild-type mice. In humans, heterozygous carriers
of UMOD mutations suffering from UAKD exhibit a decrease
of urinary uromodulin of 30% up to ,2% compared with
values of control groups (9,33). The potential dominant negative
role of mutant uromodulin on the maturation and trafficking of
wild-type protein might depend on the severity of disturbance
of ER homeostasis (32). Homozygous mutant mice of both
Umod mutant lines exhibit an earlier onset and more pronounced
renal dysfunction than their heterozygous mutant littermates.
This is in line with a human report about a consanguineous
family, where homozygous carriers of a UMOD mutation had
a more pronounced renal dysfunction on average than heterozy-
gous carriers (45), indicating the importance of allelic status on
onset and speed of progression of the disease.
Besides the alterations of kidney function, both Umod muta-
tions affect body growth and body composition. Already at ado-
lescence, UmodC93F mutant mice exhibited a reduced body
weight compared with wild-type controls. This occurs at the
time period where also renal function of the animals starts to
be impaired. Thus, reduced body weight gain of mutant mice
is not a consequence of azotemia and chronic renal insufficiency,
as young mutant mice exhibit only mild signs of renal dysfunc-
tion. Other groups published two transgenic mouse lines, the first
expressing C148W human mutant uromodulin but exhibiting no
clinical renal phenotype even in aged mice and the later expres-
sing the corresponding C147W murine mutant uromodulin exhi-
biting a clinical phenotype with features of UAKD and renal
failure with tubular necrosis at an age of 6 months (46,47).
None of both transgenic mouse lines exhibited alterations in
body weight. The phenotypic differences between the mutant
mouse lines UmodA227T and UmodC93F and the two transgenic
mouse models might be due to a different expression level of uro-
modulin (endogenous versus transgene expression) and to the
different genetic background (C3HeB/FeJ versus C57BL/6
and FVB/N, respectively). Besides alterations in body weight
Figure 6. Quantitative evaluation of morphological kidney alterations of aged Umod mutant mice. Volume fraction (Vv) and total volume (V) of IFTA (Vv(IFTA/kid)
and V(IFTA,kid)) and inflammatory cell infiltrates (Vv(IC/kid) and V(IC,kid)) of 20–22-month-old male mice of the lines Umod
A227T and UmodC93F. Data points show
means+SEM. n ¼ 12 of wild-types, n ¼ 6 per genotype and line of mutants. ∗P , 0.05; ∗∗P , 0.01; ∗∗∗P , 0.001; ahomozygous versus wild-type; bheterozygous
versus wild-type; chomozygous versus heterozygous of the same Umod mutant line; dhomozygous UmodC93F mutant versus homozygous UmodA227T mutant; eheter-
ozygous UmodC93F mutant versus heterozygous UmodA227T mutant.
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and body composition, phenotypic analysis of both UmodA227T
and UmodC93F mutant mice revealed alterations in plasma con-
centrations of cholesterol and triglycerides versus wild-type lit-
termates. These findings could be mouse strain-specific and
require further investigations.
Taken together, the new established mutant mouse line
UmodC93F represents a further mutant animal model for
UAKD, with the disruption of a putative disulfide bond which
is also absent in a known human UMOD mutation. Both
mutant lines, UmodC93F and UmodA227T, exhibit phenotypes
highly similar to UAKD in humans. Common features of
UAKD are TALH dysfunction due to a gain-of-toxic function
mutation of Umod, causing reduced fractional excretion of uric
acid, impaired urinary concentration ability and uremia. Onset,
severity and progression of renal dysfunction strongly depend
on the particular Umod mutation and the zygosity status,
which in turn can be attributed to the severity of the processing
and trafficking defect of uromodulin. Further studies have to
address the UPR pathway as a potential target for new therapeut-
ic strategies and to elucidate the signaling pathways responsible
for the initiation of tubular fibrosis in UAKD.
MATERIALS AND METHODS
Animals, linkage analysis and detection of the causative
mutation
The mutant mouse lines UREHD1 (25) and the recently charac-
terized mouse line UmodA227T (20) were used in this study. Both
mouse lines were established within the Munich ENU mouse
mutagenesis project which was carried out on the inbred
C3HeB/FeJ (C3H) genetic background (25,48). Mouse hus-
bandry and breeding were described previously (25). All
animal experiments were carried out under the approval of the
responsible animal welfare authority.
Line UREHD1 exhibited an increase of plasma urea which
was heritable in an autosomal-dominant manner. For linkage
analyses, phenotypic UREHD1 mutant mice were mated to
BALB/c mice for two generations, and G1 and G2 offspring
were phenotypically classified in mice exhibiting normal or
increased plasma urea levels, respectively. DNA of phenotypic
mutant G2 offspring were used for genome-wide linkage ana-
lyses and further fine mapping as described previously (20,25).
Umod (NM_009470) was selected for sequence analysis as a
positional candidate gene. Genotyping of mice was performed
by allele-specific PCR. Primer sequences are available on
request.
Clinical-chemical analyses
Analyses of blood and urine parameters were carried out as
described previously (20,49). Plasma creatinine values were
determined enzymatically (Biomed), while urine creatinine con-
centration was determined by the Jaffé method. Cystatin C con-
centration in plasma was determined by the mouse Cystatin C
ELISA (BioVendor) as used elsewhere (50).
Figure 7. Proposed model of the pathogenesis in UAKD. Pathogenesis of UAKD includes alterations occurring at the cellular level, the resulting clinical findings and
parameters which influence onset, severity and progression of clinical signs. First diagnosis of renal dysfunction and/or hyperuricemia in humans suffering from
UAKD is reported from 9 months up to 65 years of age (5,6,9,35,39,45,54). End-stage renal disease (ESRD) was diagnosed on some but not all humans suffering
from UAKD, whereas the patients with ESRD had an age of 6 up to 66 years of age (most of them .40 years) (9,35,38,45,55). Progressed histopathological alterations
described in the kidneys of humans suffering from UAKD are interstitial fibrosis, thickened basement membrane, interstitial infiltrates of inflammatory mononuclear
cells, tubular atrophy and, rarely, tubular or glomerular cysts (8,35,36,38,40).
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Analyses of urine and kidney function
Body weight, water consumption and urine excretion were mea-
sured using metabolic cages for single mice (Tecniplast). Urine
osmolality was determined by freezing point depression ana-
lysis. Daily excretion of solutes was measured. Performance of
metabolic cage analyses, calculations of creatinine clearance
and of fractional excretion of a solute x (FEx) was performed
as described previously (20,51).
Body growth and skeletal analysis
To determine postnatal body growth, measurement of body
weight started at day of birth (d0) or one day after (d1), and
was performed weekly until an age of 18 weeks. Body weights
of mice were determined to the nearest 0.1 g. For skeletal ana-
lysis, dual-energy X-ray absorptiometry (DXA) analyses were
performed as described (20,49).
Morphological analysis
Histological analyses of kidneys were performed as described
previously (20). Staining of histological kidney sections
included hematoxylin and eosin (H&E), Giemsa, Masson-
Trichrom and PAS-silver for paraffin sections and toluidine
blue for semi-thin sections. Immunohistochemistry using the in-
direct immunoperoxidase technique was performed with a rabbit
polyclonal antibody against human THP (H-135; Santa Cruz
Biotechnology) and a rabbit polyclonal antibody against rat
NKCC2 (Alpha Diagnostic International). For electronmicro-
scopic analysis, kidneys were fixed with 3% glutaraldehyde in
PBS (pH 7.2) via orthograde vascular perfusion, 1 mm3
samples of the renal cortex were postfixed by immersion with
the same fixative for one day and processed as described (25).
Colocalization of uromodulin with the two ER markers
protein disulphide isomerase (PDI) and 78 kDa glucose regu-
lated protein (GRP78, BiP), and the Golgi maker giantin was
studied by multicolor immunofluorescence. The following
primary antibodies were used: polyclonal goat antiserum
against human uromucoid (MP Biomedicals), polyclonal
rabbit anti PDI IgG (Abcam), polyclonal rabbit anti GRP78/
BiP IgG (Abcam) and polyclonal rabbit anti giantin IgG
(Abcam). All secondary antibodies were produced in donkey
and coupled to FITC or Cy3 (Dianova). Embedding of slides
was done with Vectashield antifade solution (Vector
Table 4. Features of alterations in UAKD and comparison between line UmodC93F, line UmodA227T and UAKD in humans
(I) Features of alterations in UAKD
Parameter Mutant mice Human
Histological alterations
Of TALH cells Accumulation of uromodulin Accumulation of uromodulin
ER hyperplasia ER hyperplasia
Of the kidney Interstitial fibrosis (aged mice) Interstitial fibrosis (progressed alterations)
Interstitial infiltrates (aged mice) Interstitial infiltrates (progressed alterations)
Tubular or glomerular cysts (aged mice) Tubular or glomerular cysts (inconstant)
Tubular atrophy (aged mice) Tubular atrophy
Clinical findings
Renal findings Azotemia Azotemia
Reduced FEuric acid Reduced FEuric acid
Urinary concentration defect Urinary concentration defect
Reduced excretion of uromodulin Reduced excretion of uromodulin
Extrarenal findings Alteration in energy metabolism No data available
Mild osteopenia
(II) Comparison between line UmodC93F, line UmodA227T and UAKD in humans
(A) Cellular level
Parameter UmodA227T UmodC93F UAKD in humans
het Homo het homo
Onset of maturation defect n.d. n.d. Already present at
2 weeks of age
No data available
Severity of maturation defect (parameter:
uromodulin excretion)
+ ++ ++ +++ In-vitro: mutations classified in two groups of severity, however,
no correlation to in-vivo data
(B) Clinical findings
Parameter UmodA227T UmodC93F UAKD in humans
het homo het homo
Onset of hyperuricemia/gout — — — — First diagnosis: 1st to 7th decade, no correlation to the mutation




7 weeks (f) 2 weeks
(f)
Severity of kidney dysfunction + ++ ++ +++ No correlation to the mutation
(C) Parameters influencing onset, severity and progression of UAKD
Parameter Mutant mice Human
Zygosity Homozygote .. Heterozygote Homozygote .. Heterozygote (assumed, one case report)
Type of Umod mutation C93F .. A227T Assumed by in-vitro data, however, no correlation to in-vivo data
Genetic background Same inbred mouse strain (C3H) Heterogeneous (putative impact of modifier genes)
Environment (e.g. housing, nutrition) Identical Heterogeneous
FEuric acid, fractional excretion of uric acid; n.d., not done; +, ++, +++: degree of alterations of the corresponding parameter; m, male; f, female.
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Laboratories) containing DAPI as a nuclear counterstain.
Confocal optical sections (pixel size 50 × 50 nm, pinhole
size 1 Airy unit corresponding to an optical thickness of
0.7–1 mm) were recorded using a confocal laser scanning
microscope (LSM 510 Meta; Zeiss) equipped with a 40× Plan-
Neofluar oil immersion objective (NA 1.3). A polychromatic
multichannel detector (Meta detector; Zeiss) was used to
discriminate autofluorescence from immunofluorescence
signals.
Volume fractions of IFTA and inflammatory cell infiltrates
in the kidney (Vv(IFTA/kid) and Vv(IC/kid)) were determined
by the point-counting method (52) using systematically
sampled paraffin kidney sections (PAS-silver stained sections
for IFTA and Giemsa stained sections for IC). Test fields
were selected in paraffin sections by systematic random sam-
pling using an image analyzing system which consisted of
a light microscope (BX41, Olympus, Germany), a color video
camera (DP72, Olympus, Germany) and the software new
CASTTM (computer-assisted stereological toolbox, Visio-
pharm, Denmark). Vv(IFTA/kid) and Vv(IC/kid) were calculated
by dividing the sum of points hitting IFTA and inflammatory





sum of points hitting renal tissue [
∑
P(kid)]. The kidney
volume (V(kid)) was calculated by dividing its weight by its
specific weight (1.05 mg/mm3). The total volumes of IFTA
and inflammatory cells (V(IFTA,kid) and V(IC,kid)) were calculated
as the products of the respective volume fraction (Vv(IFTA/kid)
and Vv(IC /kid)) and V(kid).
Western blot analyses
Twenty-four-hour urine samples, standardized for equal creatin-
ine levels, were denatured by boiling after addition of beta-
mercaptoethanol and loaded on 8% SDS-polyacrylamide
minigels. Blotting and immunodetection were performed as
described (53). For detection of urinary uromodulin, goat
antiserum against human uromucoid (MP Biomedicals) was
used. Signal intensities were quantified using ImageQuant
(GE Healthcare).
For western blot analyses of renal homogenates, whole kidneys
were homogenized in extraction buffer (20 mM Tris, 2%
Triton-X100, 20% 5× Laemmli buffer). Protein concentration
was determined by BCA assay. Equal amounts of denatured pro-
teins were loaded per lane on 8% SDS-polyacrylamide minigels.
For detection of renal uromodulin, a rabbit polyclonal antibody
against human THP (H-135; Santa Cruz Biotechnology) was
used.
Statistical analysis
Data are shown as means+SD or SEM as indicated. If the sum
of n1 and n2 ≤ 15, data were analyzed by using exact Fisher–
Pitman test. If the number of animals tested and compared
were .15 (sum of n1 and n2), unpaired Student’s t-tests were
used. In cases of multiple comparisons, Holm-Bonferroni cor-
rection was performed. Detailed information about the number
of animals per experiment is given in Supplementary Material,
Table S1.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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